Changmin Park

Title: Changmin Park: Innovator in Pharmaceutical Chemistry

Introduction

Changmin Park is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on isoquinolinone derivatives and compounds for inhibiting specific enzymes related to various diseases. With a total of 2 patents, his inventions are paving the way for advancements in medical treatments.

Latest Patents

Changmin Park's latest patents include a method for preparing isoquinolinone derivatives and a pharmaceutical composition aimed at preventing or treating poly(ADP-ribose) polymerase-1 (PARP-1)-related diseases. The isoquinolinone derivatives he developed exhibit an excellent PARP-1 inhibitory effect at nanomolar concentrations. Additionally, they demonstrate a remarkable cytoprotective effect on ophthalmic diseases, particularly retinal disorders. His second patent involves a novel compound for inhibiting human 11-β-hydroxy steroid dehydrogenase type 1 (11β-HSD1), which shows excellent activity and solubility, making it efficient for formulation and transfer.

Career Highlights

Throughout his career, Changmin Park has worked with reputable companies such as Digmbio Inc. and Hyundai Pharm Co., Ltd. His work in these organizations has allowed him to collaborate with other talented professionals in the field, further enhancing his contributions to pharmaceutical innovations.

Collaborations

Some of his notable coworkers include Soonyoung Moon and Younghoon Kim. Their collaborative efforts have played a crucial role in advancing the research and development of new pharmaceutical compositions.

Conclusion

Changmin Park's innovative work in pharmaceutical chemistry, particularly in developing isoquinolinone derivatives and enzyme inhibitors, showcases his commitment to improving medical treatments. His contributions are significant in the ongoing quest for effective therapies for various diseases.